-

Hugel Aesthetics Resubmits Biologics License Application for LetibotulinumtoxinA for Injection for Glabellar Lines to the FDA

BLA Resubmission to be Filed Today

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Hugel America, Inc. (Hugel Aesthetics) announced today that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for letibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines.

The resubmission follows the receipt of a Complete Response Letter (CRL) from the FDA in March 2022, which required additional data to complete the review of the BLA. Deficiencies cited by the FDA in the CRL were primarily associated with chemistry, manufacturing, controls (CMC), and general updates.

Jim Hartman, President and COO commented, “Today we are resubmitting our BLA and look forward to receiving notice next month of the FDA’s acceptance of our resubmission and the assignment of a new FDA action date.”

About Hugel Aesthetics

Hugel Aesthetics is a division of the global medical aesthetics leader, Hugel, Inc., focused on commercializing a synergistic aesthetic portfolio in the United States, Canada, and Australia.

Hugel Aesthetics is dedicated to making aesthetics more attainable for all. For more information, visit: www.hugel-aesthetics.com

Contacts

Kayleigh Adam, Alison Brod Marketing Communications, kayleigh@abmc-us.com

Industry:

Hugel America, Inc.

Release Versions
English

Contacts

Kayleigh Adam, Alison Brod Marketing Communications, kayleigh@abmc-us.com

More News From Hugel America, Inc.

Croma Australia Pty Ltd, a subsidiary of Hugel Aesthetics, Receives TGA Approval in Australia for LETYBO (letibotulinumtoxinA) for the Treatment of Glabellar Lines

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Hugel America, Inc., (Hugel Aesthetics), today announced it received Therapeutic Goods Administration (TGA) approval for LETYBO (letibotulinumtoxinA) to treat moderate-to-severe glabellar (frown) lines in adults. "We are thrilled with the TGA’s approval of LETYBO. This is a major milestone for Croma Australia as we focus on becoming a top aesthetics brand in Australia,” stated James Hartman, President, Hugel Aesthetics. “We are excited to deliver quality...

Hugel Aesthetics Receives FDA Acceptance of BLA Resubmission for LetibotulinumtoxinA for Injection for Glabellar Lines

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Hugel America, Inc. (Hugel Aesthetics) announced today the acceptance of its Biologics License Application for letibotulinumtoxinA, by the U.S. Food and Drug Administration (“FDA”). The FDA considered the resubmission a Class 2 response and has assigned a April 6, 2023 action date per the Prescription Drug User Fee Act (PDUFA). Jim Hartman, President of Hugel Aesthetics, stated, “We have worked diligently to advance our regulatory submission of letibotuli...

Hugel Aesthetics to Present Data from Phase 3 Clinical Trial At 2022 American Society of Dermatologic Surgery Annual Meeting

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Hugel America, Inc. (Hugel Aesthetics) announced today that the company will have an oral presentation at the American Society for Dermatologic Surgery (ASDS) annual meeting (Oct. 6-10, 2022 in Denver, CO) highlighting data from its phase 3 clinical trial, BLESS III, assessing the efficacy of letibotulinumtoxinA in improving the psychosocial health-related quality of life (QoL) of subjects with moderate to severe glabellar lines. “Hyperfunctional glabella...
Back to Newsroom